The ubiquitin-proteasome system - Micro target for macro intervention?

International Journal of Cardiovascular Interventions

Volumn 7, Issue 1, 2005, Pages 5-13

  Herrmann, Joerg ^a,c   Ciechanover, Aaron ^b   Lerman, Lilach O ^a   Lerman, Amir ^a  

^a MAYO CLINIC   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c MAYO CLINIC ROCHESTER   (United States)

Author keywords

Atherosclerosis; Inflammation; Neointima; Pathology

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; EPOXOMICIN; LACTACYSTIN; LACTONE DERIVATIVE; MG 115; MG 262; NORLEUCINE; PEPTIDE DERIVATIVE; PR 11; PR 39; PROTEASOME; PROTEASOME INHIBITOR; UBIQUITIN; UNCLASSIFIED DRUG; YU 101;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR SYSTEM; CELL PROLIFERATION; DRUG ELUTING STENT; DRUG TARGETING; HUMAN; INFLAMMATION; INTIMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN TARGETING; RESTENOSIS; REVIEW;

APOPTOSIS; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CELL PROLIFERATION; CORONARY ARTERIOSCLEROSIS; CORONARY VESSELS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; SENSITIVITY AND SPECIFICITY; UBIQUITIN-PROTEIN LIGASE COMPLEXES;

EID: 20344373169     PISSN: 14628848     EISSN: None     Source Type: Journal    
DOI: 10.1080/14628840510011234     Document Type: Review

References (94)

1. Sousa JE, Costa MA, Tuzcu EM, Yadav JS, Ellis S. New frontiers in interventional cardiology. Circulation. 2005;111:671-81.
2. Rowinsky EK. Targeting the molecular target of rapamycin (mTOR). Curr Opin Oncol. 2004;16:564-75.
3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253-65.
4. Goldstein G, Scheid M, Hammerling U, Schlesinger DH, Niall HD, Boyse EA. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci USA. 1975;72:11-5.
5. Ciechanover A, Elias S, Heller H, Ferber S, Hershko A. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes. J Biol Chem. 1980;255:7525-8.
6. Hershko A. Ubiquitin-mediated protein degradation. J Biol Chem. 1988;263:15237-40.
7. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996;335:1897-905.
8. Ciechanover A, Orian A, Schwartz AL. The ubiquitin-mediated proteolytic pathway: mode of action and clinical implication. J Cell Biochem Suppl. 2000;34:40-51.
9. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65:801-47.
10. Weissman AM. Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol. 2001;2:169-78.
11. Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer. 2001;85:297-302.
12. Nyman TA, Matikainen S, Sareneva T, Julkunen I, Kalkkinen N. Proteome analysis reveals ubiquitin-conjugating enzymes to be a new family of interferon-alpha-regulated genes. Eur J Biochem. 2000;267:4011-9.
13. Gaczynska M, Rock KL, Goldberg AL. Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature. 1993;365:264-7.
14. Davies KJ. Degradation of oxidized proteins by the 20S proteasome. Biochimie. 2001;83:301-10.
15. Kornitzer D, Ciechanover A. Modes of regulation of ubiquitin-mediated protein degradation. J Cell Physiol. 2000;182:1-11.
16. Bachmair A, Finley D, Varshavsky A. In vivo half-life of a protein is a function of its amino-terminal residue. Science. 1986;234:179-86.
17. Kwon YT, Kashina AS, Davydov IV, et al. An essential role of N-terminal arginylation in cardiovascular development. Science. 2002;297:96-9.
18. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa] B activity. Annu Rev Immunol. 2000;18:621-63.
19. Hon WC, Wilson MI, Harlos K, et al. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. Nature. 2002;417:975-8.
20. Bercovich B, Stancovski I, Mayer A, et al. Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J Biol Chem. 1997;272:9002-10.
21. Dai RM, Chen E, Longo DL, Gorbea CM, Li CC. Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. J Biol Chem. 1998;273:3562-73.
22. Grant EP, Michalek MT, Goldberg AL, Rock KL. Rate of antigen degradation by the ubiquitin-proteasome pathway influences MHC class I presentation. J Immunol. 1995;155:3750-88.
23. Cenciarelli C, Hou D, Hsu KC, et al. Activation-induced ubiquitination of the T cell antigen receptor. Science. 1992;257:795-7.
24. Zhang J, Bardos T, Li D, et al. Cutting edge: regulation of T cell activation threshold by CD28 costimulation through targeting Cbl-b for ubiquitination. J Immunol. 2002;169:2236-40.
25. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78:773-85.
26. Naujokat C, Hoffmann S. Role and function of the 26S proteasome in proliferation and apoptosis. Lab Invest. 2002;82:965-80.
27. Jesenberger V, Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol. 2002;3:112-21.
28. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science. 2000;288:874-7.
29. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999;340:115-26.
30. De Nigris F, Lerman LO, Condorelli M, Lerman A, Napoli C. Oxidation-sensitive transcription factors and molecular mechanisms in the arterial wall. Antioxid Redox Signal. 2001;3:1119-30.
31. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol. 2000;20:E83-8.
32. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001;107:255-64.
33. Deng L, Wang C, Spencer E, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 2000;103:351-61.
34. Orian A, Gonen H, Bercovich B, et al. SCF(beta)(-TrCP) ubiquitin ligase-mediated processing of NF-kappaB p105 requires phosphorylation of its C-terminus by IkappaB kinase. EMBO J. 2000;19:2580-91.
35. Jahngen-Hodge J, Obin MS, Gong X, et al. Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J Biol Chem. 1997;272:28218-26.
36. Reinheckel T, Sitte N, Ullrich O, Kuckelkorn U, Davies KJ, Grune T. Comparative resistance of the 20S and 26S proteasome to oxidative stress. Biochem J. 1998;335:637-42.
37. Bulteau AL, Lundberg KC, Humphries KM, et al. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J Biol Chem. 2001;276:30057-63.
38. Hyun DH, Lee MH, Halliwell B, Jenner P. Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end-product of lipid peroxidation: a mechanism contributing to neurodegeneration? J Neurochem. 2002;83:360-70.
39. Ruef J, Moser M, Bode C, Kubler W, Runge MS. 4-hydroxynonenal induces apoptosis, NF-kappaB-activation and formation of 8-isoprostane in vascular smooth muscle cells. Basic Res Cardiol. 2001;96:143-50.
40. Schmitz ML, Bacher S, Kracht M. I kappa B-independent control of NF-kappa B activity by modulatory phosphorylations. Trends Biochem Sci. 2001;26:186-90.
41. Herrmann J, Gulati R, Napoli C, et al. Oxidative stress-related increase in ubiquitination in early coronary atherosclerosis. FASEB J. 2003;10:1096/fj.02-0841fje.
42. Wilson SH, Caplice NM, Simari RD, Holmes DR Jr, Carlson PJ, Lerman A. Activated nuclear factor-kappaB is present in the coronary vasculature in experimental hypercholesterolemia. Atherosclerosis. 2000;148:23-30.
43. Kikuchi J, Furukawa Y, Kubo N. Induction of ubiquitin-conjugating enzyme by aggregated low density lipoprotein in human macrophages and its implications for atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:128-34.
44. Vieira O, Escargueil-Blanc I, Jürgens G, et al. Oxidized LDLs alter the activity of the ubiquitin-proteasome pathway: potential role in oxidized LDL-induced apoptosis. FASEB J. 2000;14:532-42.
45. Herrmann J, Edwards WD, Schwartz RS, et al. Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes. J Am Coll Cardiol. 2002;40:1919-27.
46. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P. Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol. 1996;16:19-27.
47. Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P. Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:2200-8.
48. Kim K. Proteasome inhibitors sensitize human vascular smooth muscle cells to Fas (CD95)-mediated death. Biochem Biophys Res Commun. 2001;281:305-10.
49. Cui H, Matsui K, Omura S, et al. Proteasome regulation of activation-induced T cell death. Proc Natl Acad Sci USA. 1997;94:7515-20.
50. van der Wal AC, Piek JJ, de Boer OJ, et al. Recent activation of the plaque immune response in coronary lesions underlying acute coronary syndromes. Heart. 1998;80:14-8.
51. Liuzzo G, Goronzy JJ, Yang H, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000;101:2883-8.
52. Weyand CM, Goronzy JJ, Liuzzo G, Kopecky SL, Holmes DR Jr, Frye RL. T-cell immunity in acute coronary syndromes. Mayo Clin Proc. 2001;76:1011-20.
53. Wang X, Luo H, Chen H, Duguid W, Wu J. Role of proteasomes in T cell activation and proliferation. J Immunol. 1998;160:788-801.
54. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:1876-90.
55. Yoshimura S, Bondeson J, Brennan FM, Foxwell BM, Feldmann M. Role of NFkappaB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI. Eur J Immunol. 2001;31:1883-93.
56. Igarashi M, Kato T, Ohnuma H, Morita Y, Kawanami T, Sasaki H. Ubiquitin expression in atherosclerotic lesions of wistar fatty and wistar lean rats. Artery. 1994;21:256-70.
57. Thyberg J, Blomgren K. Effects of proteasome and calpain inhibitors on the structural reorganization and proliferation of vascular smooth muscle cells in primary culture. Lab Invest. 1999;79:1077-88.
58. Herrmann J, Ciechanover A, Lerman LO, Lerman A. The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res. 2004;61:11-21.
59. Adam PJ, Weissberg PL, Gary NR, Shanahan CM. Polyubiquitin is a new phenotypic marker of contractile vascular smooth muscle cells. Cardiovasc Res. 1997;33:416-21.
60. Stone DH, Sivamurthy N, Contreras MA, Fitzgerald L, LoGerfo FW, Quist WC. Altered ubiquitin/proteasome expression in anastomotic intimal hyperplasia. J Vasc Surg. 2001;34:1016-22.
61. Meiners S, Laule M, Rother W, et al. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation. 2002;105:483-9.
62. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis. 1989;78:225-8.
63. Ohkita M, Takaoka M, Kobayashi Y, Itoh E, Uemachi H, Matsumura Y. Involvement of proteasome in endothelin-1 production in cultured vascular endothelial cells. Jpn J Pharmacol. 2002;88:197-205.
64. Okamoto H, Takaoka M, Ohkita M, Itoh M, Nishioka M, Matsumura Y. A proteasome inhibitor lessens the increased aortic endothelin-1 content in deoxycorticosterone acetate-salt hypertensive rats. Eur J Pharmacol. 1998;350:R11-2.
65. Takaoka M, Ohkita M, Itoh M, Kobayashi Y, Okamoto H, Matsumura Y. A proteasome inhibitor prevents vascular hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol. 2001;28:466-8.
66. Takaoka M, Okamoto H, Ito M, Nishioka M, Kita S, Matsumura Y. Antihypertensive effect of a proteasome inhibitor in DOCA-salt hypertensive rats. Life Sci. 1998;63:PL65-70.
67. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8:739-58.
68. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349-60.
69. Burger AM, Seth AK. The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications. Eur J Cancer. 2004;40:2217-29.
70. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-17.
71. Podar K, Shringarpure R, Tai YT, et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004;64:7500-6.
72. Kim SC, Rho MC, Lee HS, Kim YK, Kim K. Caspase-3-dependent apoptosis in vascular smooth muscle cell by proteasome inhibition. J Cardiovasc Pharmacol. 2003;42:554-60.
73. Glockzin S, von Knethen A, Scheffner M, Brune B. Activation of the cell death program by nitric oxide involves inhibition of the proteasome. J Biol Chem. 1999;274:19581-6.
74. Song PH, Xie HY, Zheng SS, Wu J. The inhibitory role of lactacystin and beta-lactacystin on T-cell activation and proliferation. Acta Biochim Biophys Sin. 2004;36:123-7.
75. Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J. A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation. 2001;72:196-202.
76. Read MA, Neish AS, Luscinskas FW, Palombella VJ, Maniatis T, Collins T. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity. 1995;2:493-506.
77. Cobb RR, Felts KA, Parry GC, Mackman N. Proteasome inhibitors block VCAM-1 and ICAM-1 gene expression in endothelial cells without affecting nuclear translocation of nuclear factor-kappa B. Eur J Immunol. 1996;26:839-45.
78. Kalogeris TJ, Laroux FS, Cockrell A, et al. Effect of selective proteasome inhibitors on TNF-induced activation of primary and transformed endothelial cells. Am J Physiol. 1999;276:C856-64.
79. Parry GC, Martin T, Felts KA, Cobb RR. IL-1beta-induced monocyte chemoattractant protein-1 gene expression in endothelial cells is blocked by proteasome inhibitors. Arterioscler Thromb Vasc Biol. 1998;18:934-40.
80. Dagia NM, Goetz DJ. A proteasome inhibitor reduces concurrent, sequential, and long-term IL-1 beta- and TNF-alpha-induced ECAM expression and adhesion. Am J Physiol Cell Physiol. 2003;285:C813-22.
81. Jiang J, Cyr D, Babbitt RW, Sessa WC, Patterson C. Chaperone-dependent regulation of endothelial nitric-oxide synthase intracellular trafficking by the co-chaperone/ubiquitin ligase CHIP. J Biol Chem. 2003;278:49332-41.
82. Stangl V, Lorenz M, Meiners S, et al. Long-term upregulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J. 2004;18:272-9.
83. Govers R, de Bree P, Rabelink TJ. Involvement of the proteasome in activation of endothelial nitric oxide synthase. Life Sci. 2003;73:2225-36.
84. Oikawa T, Sasaki T, Nakamura M, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun. 1998;246:243-8.
85. Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res. 2001;7:1419-28.
86. Bell SE, Mavila A, Salazar R, et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci. 2001;114:2755-73.
87. Stoklosa T, Golab J, Wojcik C, et al. Increased local vascular endothelial growth factor expression associated with antitumor activity of proteasome inhibitor. Apoptosis. 2004;9:193-204.
88. Mezquita J, Mezquita B, Pau M, Mezquita C. Down-regulation of Flt-1 gene expression by the proteasome inhibitor MG262. J Cell Biochem. 2003;89:1138-47.
89. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-76.
90. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. FASEB J. 2000;14:65-77.
91. Meiners S, Hocher B, Weller A, et al. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension. 2004;44:471-7.
92. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part I. Circulation. 2003;107:2274-9.
93. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology: drug-eluting stents: Part II. Circulation. 2003;107:2383-9.
94. Ostrowska JK, Wojtukiewicz MZ, Chabielska E, Buczko W, Ostrowska H. Proteasome inhibitor prevents experimental arterial thrombosis in renovascular hypertensive rats. Thromb Haemost. 2004;92:171-7.